Company logo

JNJ - Johnson & Johnson

NYSE -> Healthcare -> Drug Manufacturers—General
New Brunswick, United States
Type: Equity

JNJ price evolution
JNJ
(in millions $) 1 Feb 2024 31 Jan 2024 2 Aug 2023 3 May 2023
Current assets
Cash $3340 $21859 $4430 $4674
Short term investments $1068 $3783 $7322
Net receivables $14873 $14873 $16777 $16350
Inventory $11181 $11181 $12888 $12809
Total current assets $53495 $53495 $60567 $64388
Long term investments
Property, plant & equipment $20898 $19898 $20576 $20174
Goodwill & intangible assets $70733 $71145 $91686
Total noncurrent assets $114063 $112358 $131119
Total investments $1068 $3783 $7322
Total assets $167558 $167558 $191686 $195969
Current liabilities
Accounts payable $9632 $9632 $10443 $9909
Deferred revenue
Short long term debt $3451 $3870 $11701
Total current liabilities $46282 $46282 $54170 $60373
Long term debt $25881 $25881 $33901 $34928
Total noncurrent liabilities $52502 $50463 $61107
Total debt $29332 $29921 $45602
Total liabilities $98784 $98784 $116537 $125100
Shareholders' equity
Retained earnings $153843 $153843 $129381 $124558
Other shareholder equity -$12526 -$12527 -$13129 -$12616
Total shareholder equity $68774 $71228 $75149
(in millions $) 31 Jan 2024 1 Feb 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $21859 $4926 $14487 $13985
Short term investments $1068 $9392 $17121 $11200
Net receivables $14873 $16160 $15283 $13576
Inventory $11181 $12483 $10387 $9344
Total current assets $53495 $55294 $60979 $51237
Long term investments $2193
Property, plant & equipment $19898 $20903 $18962 $18766
Goodwill & intangible assets $70733 $93556 $81638 $89795
Total noncurrent assets $114063 $132084 $121039 $123657
Total investments $1068 $9392 $17121 $11200
Total assets $167558 $187378 $182018 $174894
Current liabilities
Accounts payable $9632 $11703 $11055 $9505
Deferred revenue
Short long term debt $3451 $12771 $3766 $2631
Total current liabilities $46282 $55802 $45226 $42493
Long term debt $25881 $26888 $29985 $32635
Total noncurrent liabilities $52502 $54772 $62769 $69123
Total debt $29332 $39659 $33751 $35266
Total liabilities $98784 $110574 $107995 $111616
Shareholders' equity
Retained earnings $153843 $128345 $123060 $113890
Other shareholder equity -$12527 -$12940 -$13058 -$15242
Total shareholder equity $68774 $76804 $74023 $63278
(in millions $) 1 Feb 2024 31 Jan 2024 2 Aug 2023 3 May 2023
Revenue
Total revenue $21395 $25530 $24746
Cost of revenue
Gross Profit $14597 $17318 $16351
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $9869 $10434 $16929
Operating income
Income from continuing operations
EBIT
Income tax expense $694 $1618 -$669
Interest expense $212 $23 $20
Net income
Net income $4049 $5144 -$68
Income (for common shares)
(in millions $) 1 Feb 2024 31 Dec 2022 2 Feb 2022 31 Dec 2020
Revenue
Total revenue $85159 $94943 $82584
Cost of revenue $31089 $28427
Gross Profit $58606 $63854 $54157
Operating activities
Research & development $14603 $12159
Selling, general & administrative $24765 $22084
Total operating expenses $43231 $40472 $34671
Operating income $23382 $19486
Income from continuing operations
EBIT $22001 $16698
Income tax expense $1736 $3784 $1783
Interest expense $489 $276 $201
Net income
Net income $35153 $17941 $14714
Income (for common shares) $17941 $14714
(in millions $) 1 Feb 2024 31 Dec 2023 2 Aug 2023 3 May 2023
Net income $4049
Operating activities
Depreciation $1843
Business acquisitions & disposals -$349
Stock-based compensation $178
Total cash flows from operations $7863
Investing activities
Capital expenditures -$1589
Investments $632
Total cash flows from investing $878 -$1202 -$461 $3315
Financing activities
Dividends paid -$11770 -$2865 -$6034 -$2942
Sale and purchase of stock -$29
Net borrowings -$1377
Total cash flows from financing -$15825 -$4655 $147 $6138
Effect of exchange rate -$112 $125 -$69 $28
Change in cash and equivalents $7732 $2131 $7056 $12738
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $35153 $17941 $20878 $14714
Operating activities
Depreciation $7486 $6970 $7390 $7231
Business acquisitions & disposals -$112 -$17109 $651 -$7018
Stock-based compensation $1162 $1138 $1135 $1005
Total cash flows from operations $22791 $21194 $23410 $23536
Investing activities
Capital expenditures -$4543 -$4009 -$3652 -$3347
Investments $5521 $8976 -$5174 -$8952
Total cash flows from investing $878 -$12371 -$8683 -$20825
Financing activities
Dividends paid -$11770 -$11682 -$11032 -$10481
Sale and purchase of stock -$3960 -$4706 -$2420 -$2107
Net borrowings -$2953 $7424 -$709 $7095
Total cash flows from financing -$15825 -$8871 -$14047 -$6120
Effect of exchange rate -$112 -$312 -$178 $89
Change in cash and equivalents $7732 -$360 $502 -$3320
Fundamentals
Market cap $380.78B
Enterprise value N/A
Shares outstanding 2.41B
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q -13.54%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share 1.39
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.44
Net debt/EBITDA N/A
Current ratio 1.16
Quick ratio 0.91